Premium
Preliminary clinical studies with ibenzmethyzin
Author(s) -
DeVita Vincent T.,
Serpick Arthur,
Carbone Paul P.
Publication year - 1966
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196674542
Subject(s) - nausea , vomiting , medicine , ataxia , somnolence , depression (economics) , bone marrow , toxicity , adverse effect , anesthesia , psychiatry , economics , macroeconomics
Ibenzmethyzin was administered to 35 patients with neoplastic diseases. In 6 patients, daily, semiweekly, or weekly injections of 300 to 1,600 mg. per square meter were given. The adverse reactions were gastrointestinal and neurologic: nausea, vomiting, ataxia, confusion, and somnolence. When given in daily oral doses of 125 to 300 mg. per square meter, the drug caused nausea and vomiting and bone marrow depression. With oral administration, a dose of 125 mg. per square meter with interruption rather than downward modification to prevent bone marrow toxicity is recommended. Antitumor activity was seen in 5 of 10 patients with Hodgkin's disease and one with malignant melanoma. It is suggested that ibenzmethyzin metabolism or binding at the active site may be rate limiting.